Downregulation of CYP2A6 and CYP2C8 in Tumor Tissues Is Linked to Worse Overall Survival and Recurrence-Free Survival from Hepatocellular Carcinoma

Table 2

Clinicopathological comparison grouped by CYP2A6 and CYP2C8 from GSE14520 and GSE36376.

Category	CYP2A6		P value	CYP2C8		P value
	High	Low		High	Low
GSE14520
HBV viral status (AVR-CC/CC/NA)	25/81/4	31/74/5	0.635	28/78/4	28/77/5	0.943
Alanine aminotransferase (>50/<50, U/L)	38/72	51/59	0.099	42/68	47/63	0.583
Main tumor size (>5/<5/NA, cm)	34/76/0	44/65/1	0.16	33/77/0	45/64/1	0.091
Multinodular (yes/no)	18/92	27/83	0.181	21/89	24/86	0.738
Cirrhosis (yes/no)	101/9	101/9	1.0	101/9	101/9	1.0
TNM staging (I/II/III/NA)	57/37/15/1	36/40/33/1	0.005	56/33/21/0	37/44/27/2	0.032
BCLC staging (0-A/B/C/NA)	83/9/7/1	75/13/21/1	0.039	79/8/13/0	79/14/15/2	0.357
GSE36376
Edmondson grade (I/II/III)	16/100/4	8/97/15	0.01	19/96/5	5/101/14	0.002
Tumor size (median), mm	34 (31)	40 (45)	0.203	34 (30)	42 (45)	0.081
Vascular invasion (yes/no)	51/69	84/36	<0.001	51/69	84/36	<0.001
Major portal vein invasion (yes/no)	1/119	8/112	0.036	1/119	8/112	0.036
Intrahepatic metastasis (yes/no)	17/103	38/82	0.002	18/102	37/83	0.005
Multicentric occurrence (yes/no)	8/112	5/115	0.57	7/113	6/114	1.0
Direct invasion of adjacent organ (yes/no)	3/117	2/118	1.0	3/117	2/118	1.0
AJCC staging (1/2/3/4)	66/43/8/3	36/57/25/2	<0.001	67/42/8/3	35/58/25/2	<0.001
BCLC staging (A/B/C)	75/43/2	64/48/8	0.092	80/38/2	59/53/8	0.009
Alpha fetoprotein [Median (IQR), ng/ml]	9.65 (82.2)	256.6 (4136.8)	<0.001	9.1 (61.6)	303.8 (9534.45)	<0.001

NA: not available; AVR-CC: active viral replication chronic carrier; CC: chronic carrier; IQR: interquartile range;